Similar articles

• Buprenorphine Opioid Treatment During the COVID-19 Pandemic.

  Luigi M, Luo M, Maes EJP. Luigi M, et al. JAMA Intern Med. 2021 Aug 1;181(8):1135. doi: 10.1001/jamainternmed.2021.0777. JAMA Intern Med. 2021. PMID: 33843962 No abstract available.
• TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.

  Pena E, Ahmed S. Pena E, et al. Addiction. 2020 Oct;115(10):1978-1979. doi: 10.1111/add.15143. Epub 2020 Jul 1. Addiction. 2020. PMID: 32447795 Free PMC article. No abstract available.
• Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020.

  Chalasani R, Shinabery JM, Goetz CT, Chang CH, Yang Q, Suda KJ, Gellad WF. Chalasani R, et al. J Gen Intern Med. 2021 Dec;36(12):3915-3917. doi: 10.1007/s11606-021-07083-y. Epub 2021 Aug 10. J Gen Intern Med. 2021. PMID: 34378112 Free PMC article. No abstract available.
• Use and misuse of opioid agonists in opioid addiction.

  Modesto-Lowe V, Swiezbin K, Chaplin M, Hoefer G. Modesto-Lowe V, et al. Cleve Clin J Med. 2017 May;84(5):377-384. doi: 10.3949/ccjm.84a.16091. Cleve Clin J Med. 2017. PMID: 28530896 Review.
• A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.

  Narayan A, Balkrishnan R. Narayan A, et al. Subst Abus. 2021;42(2):148-152. doi: 10.1080/08897077.2021.1900981. Epub 2021 Apr 13. Subst Abus. 2021. PMID: 33849399 Review.